UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 5, 2017

MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)

Delaware	**0-26642**	**87-0494517**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

320 Wakara Way
Salt Lake City, Utah 84108
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (801) 584-3600

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 7.01 Regulation FD Disclosure.

On September 5, 2017, Myriad Genetics, Inc. ("Myriad" or the "Company") held a conference call announcing that it has launched riskScore™, a new clinically validated precision medicine tool to enhance its myRisk® Hereditary Cancer test. A copy of the slide presentation and press release announcing the launch are furnished as Exhibit 99.1 and 99.2 to this Current Report on Form 8-K and incorporated herein by reference. [The slide presentation will also be available under the "Investors –Events & Presentations" section of Myriad's website at www.myriad.com.]

FORWARD-LOOKING STATEMENTS

Exhibits 99.1 and 99.2 may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our business, goals, strategy and financial and operational outlook. These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in the exhibits is as of the date of the exhibits, and Myriad undertakes no duty to update this information unless required by law.

ITEM 9.01 Financial Statements and Exhibits.

(d)

Exhibit Number	Description
99.1	Slide presentation dated September 5, 2017.
99.2	Press release dated September 5, 2017.

The exhibit(s) may contain hypertext links to information on our website or other parties' websites. The information on our website and other parties' websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 7.01 and in Exhibits 99.1 and 99.2 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYRIAD GENETICS, INC.

Date: September 5, 2017

By: /s/ R. Bryan Riggsbee
R. Bryan Riggsbee
Executive Vice President, Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Slide presentation dated September 5, 2017.
99.2	Press release dated September 5, 2017.

MYRIAD myRisk®
Hereditary Cancer

Enhanced with a Clinically Validated Precision Medicine Tool

riskScore™
BREAST CANCER

Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements.

The Fourth Epoch in Hereditary Cancer Testing



The Problem

Answering the **most** pressing question about cancer

Will I Get Cancer?

Patients Left Without Answers



Despite being at **high familial risk** for development of breast cancer, **fewer than 10%** carry a clinically actionable mutation

CLINICAL UNCERTAINTY

Provider and Patient Left Without a Definitive Answer

riskScore™ BREAST CANCER

Doctors Focus on “Neon Light” Patients Due to Challenge of Negative Test Report

USPSTF Eligible Population



VS

myRisk Family History



Only 10% of Patients Tested Are From the Largest Pool of Patients That Meet Criteria

riskScore™ BREAST CANCER

The Product

riskScore™
BREAST CANCER

riskScore™ is a clinically validated personalized medicine tool that predicts a woman's lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome.

riskScore guides medical management in the prevention of breast cancer morbidity and mortality.

What Does riskScore Measure?

Combines Cutting Edge Science with Best-in-Class Family History Tool

Proprietary score that combines data from >80 single nucleotide polymorphisms (SNPs) with well documented role in predicting cancer risk along with best-in-class family/personal history model (Tyrer-Cuzick model)

Results for unaffected patients with European descent (initially)

Provides residual risk for patients that are negative for myRisk test and is complimentary

SNP

A single nucleotide polymorphism (SNP) is a variation in a single nucleotide that occurs at a defined point within the genome



Tyrer-Cuzick

Tyrer-Cuzick is a best-in-class family history prediction tool that looks at family history and personal factors such as age, age at first live birth, age at menarche, age at menopause, hormone use, birth control use, and lifestyle choices to assess breast cancer risk



Advancing Genetic Risk Assessment



riskScore™ BREAST CANCER

The Science

Development and Validation of riskScore

Growing Body of Evidence

Researched 20 years of genome wide association data on SNPs in breast cancer risk

Screened > 100,000 patients to select 24,259 patient training study which identified over 80 highly predictive SNPs

10,575 patient validation study showed the SNP panel in riskScore highly predictive of breast cancer risk

Combined genetic markers with family history tool in combined validation in 1,617 patients to be presented at San Antonio Breast Cancer Symposium

riskScore™ BREAST CANCER

riskScore Data Shows Test Highly Impactful & Accurate

Risk Distribution From Combined Risk Score



SNP panel was highly statistically significant for lifetime and breast cancer risk with a p-value of 10^{-31}

Combined risk score with SNP panel and Tyrer-Cuzick was highly statistically significant for both lifetime and five-year breast cancer risk with a p-value of 10^{-34} and 10^{-38} respectively

Patients have a broad distribution of relative risk with many significantly above and below the population risk

The Report

Patient #1

CONFIDENTIAL

myRisk Genetic Result

Name: **Case Study 1** DOB: **Feb 20, 1977** Accession #: **00000006-000** Report Date: **Sept 4, 2017**

Breast Cancer riskScore™

riskScore™ BREAST CANCER

Breast Cancer riskScore™ **15.2%**

RESULT: 15.2% Remaining Lifetime Risk for Breast Cancer
0.7% 5-Year Risk for Breast Cancer

Breast Cancer riskScore™ - Remaining Lifetime Risk



BREAST CANCER RISKSCORE™ INTERPRETATION

The breast cancer riskScore™ provides an estimate of the remaining lifetime risk for breast cancer. A risk estimate greater than 20% is associated with specific modified medical recommendations, including consideration of more aggressive breast cancer screening and additional risk reduction measures. If applicable, details of these recommendations are provided in the accompanying myRisk Medical Management Tool or other supplemental material. Woman with a risk estimate below 20% may still be appropriate for consideration of modified medical management based on other clinical factors or estimates from other breast cancer risk models, such as Tyrer-Cuzick, Claus, and Gail.

BREAST CANCER RISKSCORE™ ANALYSIS DESCRIPTION

The breast cancer riskScore™ provides 5-year and remaining lifetime breast cancer risks, based on an analysis of genetic markers combinad with patient clinical and family history data. The Technical Specifications summary (https://www.myriadpro.com/documents-and-forms/technical-specifications/) describes the analysis, method, performance and interpretive criteria of this test. In some cases, due to biological or technical limitations, analyses of all ___ biomarkers may not be performed. It is unlikely that data from the un-analyzed markers would have a large impact on breast cancer risk estimates provided. ___/86 markers were analyzed for this patient. Clinical and family history data used for this analysis is shown in the Clinical and Cancer Family History Information section of this report. The accuracy of this information can significantly affect the provided breast cancer risk estimates.

Please contact Myriad Medical Services at 1-800-469-7423 X 3850 to discuss any questions regarding this result.

This **Authorized Signature** pertains to this laboratory report:

Benjamin B. Roa, PhD
Diplomate ABMG
Laboratory Director

Richard J. Wenstrup, MD
Diplomate ABMG
Chief Medical Officer

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. The patient's clinical history and test results should not be disclosed to a third party, unless related to treatment or payment for treatment, without the patient's express written authorization. It is strongly recommended that these results be communicated to the patient in a setting that includes appropriate counseling. This test was developed and its performance characteristics determined by Myriad Genetic Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that clearance or approval for laboratory-developed tests is not required.

myriad.

Patient #2

CONFIDENTIAL

myRisk Genetic Result

Name: **Case Study 3** DOB: **Feb 25, 1980** Accession #: **00000000-000** Report Date: **Sept 4, 2017**

Breast Cancer riskScore™

riskScore™ BREAST CANCER

Breast Cancer riskScore™ **33.7%**

RESULT: 33.7% Remaining Lifetime Risk for Breast Cancer
1.7% 5-Year Risk for Breast Cancer

Breast Cancer riskScore™ - Remaining Lifetime Risk



BREAST CANCER RISKSCORE™ INTERPRETATION

The breast cancer riskScore™ provides an estimate of the remaining lifetime risk for breast cancer. A risk estimate greater than 20% is associated with specific modified medical recommendations, including consideration of more aggressive breast cancer screening and additional risk reduction measures. If applicable, details of these recommendations are provided in the accompanying myRisk Medical Management Tool or other supplemental material. Women with a risk estimate below 20% may still be appropriate for consideration of modified medical management based on other clinical factors or estimates from other breast cancer risk models, such as Tyrer-Cuzick, Claus, and Gail.

BREAST CANCER RISKSCORE™ ANALYSIS DESCRIPTION

The breast cancer riskScore™ provides 5-year and remaining lifetime breast cancer risks, based on an analysis of genetic markers combinad with patient clinical and family history data. The Technical Specifications summary (https://www.myriadpro.com/documents-and-forms/technical-specifications/) describes the analysis, method, performance and interpretive criteria of this test. In some cases, due to biological or technical limitations, analyses of all ___ biomarkers may not be performed. It is unlikely that data from the un-analyzed markers would have a large impact on breast cancer risk estimates provided. ___/86 markers were analyzed for this patient. Clinical and family history data used for this analysis is shown in the Clinical and Cancer Family History Information section of this report. The accuracy of this information can significantly affect the provided breast cancer risk estimates.

Please contact Myriad Medical Services at 1-800-469-7423 X 3850 to discuss any questions regarding this result.

This **Authorized Signature** pertains to this laboratory report:

Benjamin B. Roa, PhD
Diplomate ABMG
Laboratory Director

Richard J. Wenstrup, MD
Diplomate ABMG
Chief Medical Officer

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. The patient's clinical history and test results should not be disclosed to a third party, unless related to treatment or payment for treatment, without the patient's express written authorization. It is strongly recommended that these results be communicated to the patient in a setting that includes appropriate counseling. This test was developed and its performance characteristics determined by Myriad Genetic Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that clearance or approval for laboratory-developed tests is not required.

myriad.

riskScore™ BREAST CANCER



Provides individual risk score for breast cancer based upon genetic markers and Tyrer-Cuzick

Breast Cancer Screening Guidelines

The National Comprehensive Cancer Network and the American Cancer Society recommended annual breast MRI, in addition to mammogram, for women with >20% lifetime risk of breast cancer

Uncertainty

GENETIC TEST RESULT: **NEGATIVE**

MEDICAL MANAGEMENT:

- Clinical Breast Exam and Breast Awareness

Myriad myRisk®

GENETIC TEST RESULT: **NEGATIVE**

RISKSCORE: **33.7%**

MEDICAL MANAGEMENT:

- Clinical Breast Exam and Breast Awareness
- Mammography
- MRI
- Risk Reducing Strategies

The Opportunity

Market Research Shows High Interest Level in riskScore



Physicians Believe riskScore Provides Incremental Value

"If it gets marketed to the vast public, then I think Myriad will have a test that nobody else has."

"riskScore adds another piece of the puzzle. The sum of all information adds to an increased risk."

"This is the most valuable thing a sales rep has shown me in years."

"Myriad should be commended for the development of riskScore and advancing the science as it relates to refinement of breast cancer risk."

Provides Reason for Preventive Care Doctors To Go "Deeper"



- From the "trusted advisor" in hereditary cancer
- Given low positive rate, average preventive care physician only looks for "neon light" patients
- **EVERY** patient will now have an individualized assessment of breast cancer risk
- Improved test value can drive deeper penetration
- Expands an already significant competitive moat

Myriad Will Continue to Be a Scientific Pioneer

- Commercially available as of today
- SNP Panel validation to be presented at National Society of Genetic Counselors annual meeting
- Combined validation (SNP Panel + Tyrer-Cuzick) presented at San Antonio Breast Cancer Symposium in December
- Work ongoing to identify breast cancer SNPs for additional ethnicities
- Future work will expand into other cancers

News Release

Media Contact: Ron Rogers (801) 584-3065 rrogers@myriad.com
Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com

Myriad Launches riskScore™ Beginning the Next Epoch in Hereditary Cancer Testing

Provides Individualized Breast Cancer Risk for Patients Testing Negative with the myRisk® Hereditary Cancer Test

SALT LAKE CITY, Utah, September 5, 2017 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that it has launched riskScore™, a new clinically validated precision medicine tool to enhance its myRisk® Hereditary Cancer test. riskScore quantifies a woman's risk of developing breast cancer by combining genetic markers throughout the genome with her family and clinical history.

"We have known for some time that there are other genetic and clinical factors that can modify a patient's risk for breast cancer; however, this is the first time that this information has been rigorously validated to guide patient care," said Mark C. Capone, president and CEO, Myriad Genetics. "As the pioneer in hereditary cancer research, Myriad has been stalwart in our commitment to provide answers to every patient concerned about their breast cancer risks. Through the years Myriad has expanded the number of genes tested and demonstrated an unmatched commitment to classifying uncertain variants. Now this new test will provide definitive answers to the ninety percent of patients testing negative for hereditary cancer genes and will be complimentary to patients tested with myRisk®."

riskScore is a proprietary algorithm that combines data from greater than 80 genetic markers called single nucleotide polymorphisms (SNPs), with a best-in-class family and personal history algorithm called the the Tyrer-Cuzick model. Myriad researchers optimized the genetic markers in riskScore by starting with over 100,000 patient samples and have now completed two highly statistically significant validation studies in patients of European descent demonstrating the ability of riskScore to predict breast cancer risk. These major validation studies will be presented at the National Society of Genetic Counselors Annual Conference and San Antonio Breast Cancer Symposium later this calendar year.

"Having been the leader in every major epoch in hereditary cancer testing, we feel particularly proud of the innovative research employed to develop the riskScore test," said Jerry Lanchbury, Ph.D.,

chief scientific officer, Myriad Genetics. “The test will actually provide definitive answers for a higher percentage of patients than any previous test and is based upon a rigorous clinical validation. When decisions matter, patients can rely on the quality of Myriad research.”

Conference Call and Webcast

Myriad will host an investor conference call today, Tuesday, September 5, 2017, at 4:30 p.m. ET to discuss to discuss the launch of riskScore. The dial-in number for domestic callers is (800) 624-1547. International callers may dial (303) 223-4380. All callers will be asked to reference reservation number 21857299. An archived replay of the call will be available for seven days by dialing (800) 633-8284 and entering the reservation number above. The conference call along with a slide presentation will also will be available through a live webcast at www.myriad.com.

About riskScore

riskScore is a new clinically validated personalized medicine tool that enhances Myriad’s myRisk® Hereditary Cancer test. riskScore helps to further predict a women’s lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome. The test incorporates data from greater than 80 single nucleotide polymorphisms identified through 20 years of genome wide association studies in breast cancer and was validated in our laboratory to predict breast cancer risk. This data is then combined with a best-in-class family and personal history algorithm, the Tyrer-Cuzick model, to provide every patient with individualized breast cancer risk. riskScore is offered free-of-charge as an added service to Myriad’s myRisk Hereditary Cancer test.

About Myriad Genetics

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five strategic imperatives: stabilizing hereditary cancer revenue, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the launch of riskScore, a new clinically validated precision medicine tool to enhance the Company’s myRisk® Hereditary Cancer test; the ability of the riskScore tool to provide definitive answers to the ninety percent of patients testing negative for hereditary cancer genes and being complimentary to patients tested with the myRisk test; the presentation of major validation studies for the riskScore tool at the National Society of Genetic Counselors Annual Conference and San Antonio Breast Cancer Symposium later this calendar year; the ability of the riskScore tool to actually provide definitive answers for a higher percentage of patients than any previous test; patients relying on the quality of Myriad research; the date and time of the conference call and webcast announcing the riskScore tool; and the Company’s strategic directives under the caption “About Myriad Genetics.” These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory

terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our most recent Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

###